Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Non-cash Items (2020 - 2023)

Cytek Biosciences filings provide 4 years of Non-cash Items readings, the most recent being $24.1 million for Q2 2023.

  • On a quarterly basis, Non-cash Items rose 53.53% to $24.1 million in Q2 2023 year-over-year; TTM through Jun 2023 was $24.1 million, a 53.53% increase, with the full-year FY2022 number at $4.2 million, up 32.5% from a year prior.
  • Non-cash Items hit $24.1 million in Q2 2023 for Cytek Biosciences, up from $4.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $63.9 billion in Q3 2022 to a low of $1.0 million in Q2 2020.
  • Median Non-cash Items over the past 4 years was $19.9 million (2022), compared with a mean of $9.3 billion.
  • Biggest five-year swings in Non-cash Items: skyrocketed 149515.94% in 2022 and later plummeted 99.99% in 2023.
  • Cytek Biosciences' Non-cash Items stood at $11.4 million in 2020, then surged by 1194.37% to $147.6 million in 2021, then crashed by 74.8% to $37.2 million in 2022, then crashed by 35.2% to $24.1 million in 2023.
  • The last three reported values for Non-cash Items were $24.1 million (Q2 2023), $4.4 million (Q1 2023), and $37.2 million (Q4 2022) per Business Quant data.